Clinical Trials on Purpura in Russian Federation

Total 26 results

GlaxoSmithKline

Completed

Repeated Exposure to Eltrombopag in Adults With Idiopathic Thrombocytopenic Purpura (REPEAT)

Purpura, Thrombocytopaenic, Idiopathic

Germany, Russian Federation
Novartis Pharmaceuticals

Completed

A Long-term Safety Study of Eltrombopag in Pediatric Patients With Chronic Immune (Idiopathic) Thrombocytopenic Purpura (ITP)

Purpura, Thrombocytopenic, Idiopathic

Russian Federation
Instituto Grifols, S.A.

Completed

Clinical Trial in Patients Diagnosed With Immune Thrombocytopenic Purpura (ITP)

Immune (Idiopathic) Thrombocytopenic Purpura

Spain, Russian Federation, United Kingdom
CSL Behring

Completed

Treatment of Chronic Immune Thrombocytopenic Purpura (ITP) With Intravenous Immunoglobulin IgPro10

Immune Thrombocytopenic Purpura

Poland, Ukraine, Germany, Russian Federation, Italy, United Kingdom
AO GENERIUM

Enrolling by invitation

Study of the Safety and Immunogenicity of Long-term GNR-069 Therapy in ITP Patients

Idiopathic Thrombocytopenic Purpura

Russian Federation
AO GENERIUM

Completed

Comparative Study of Clinical Efficacy and Safety of GNR-069 and Nplate in Patients With ITP

Idiopathic Thrombocytopenic Purpura

Russian Federation
Bristol-Myers Squibb

Completed

Study to Evaluate Safety and Efficacy in Adult Subjects With ITP (ITP)

Immune Thrombocytopenic Purpura

United States, Australia, United Kingdom, Canada, Georgia, Moldova, Republic of, Poland, Russian Federation
Novartis Pharmaceuticals

Completed

A Study to Assess the Ability of Eltrombopag to Induce Sustained Response Off Treatment in Subjects With ITP (TAPER)

Immune Thrombocytopenic Purpura (ITP)

Spain, Italy, Greece, Switzerland, United Kingdom, France, Turkey, Russian Federation, Brazil, Austria, Mexico, Oman, Chile, Japan, United States
GlaxoSmithKline

Completed

SB-497115 (Oral Thrombopoietin Receptor Agonist) Versus Placebo In Adults With Refractory Immune Thrombocytopenic Purpura (ITP)

Purpura, Thrombocytopaenic, Idiopathic

Thailand, Korea, Republic of, United Kingdom, New Zealand, Germany, Greece, Hong Kong, Pakistan, Poland, Romania, Russian Federation, Slovenia, Taiwan
UCB Biopharma SRL

Terminated

A Study to Assess the Efficacy, Safety, and Tolerability of Rozanolixizumab in Adult Study Participants With Persistent or Chronic Primary Immune Thrombocytopenia (ITP) (myOpportunITy2)

Primary Immune Thrombocytopenia

United States, Bulgaria, China, France, Germany, Poland, Russian Federation, Spain, Taiwan, Ukraine, United Kingdom
Symphogen A/S
Swedish Orphan Biovitrum

Completed

Open Label Trial on the Safety and Efficacy of Sym001 in the Treatment of Immune Thrombocytopenic Purpura (ITP)

Immune Thrombocytopenic Purpura

United States, Belgium, Germany, India, Israel, Poland, Romania, Russian Federation, Serbia, Spain, Ukraine, United Kingdom
GlaxoSmithKline

Completed

A Longitudinal 2-year Bone Marrow Study of Eltrombopag in Previously Treated Adults, With Chronic Immune (Idiopathic) Thrombocytopenic Purpura (ITP)

Purpura, Thrombocytopaenic, Idiopathic

Italy, Germany, Hong Kong, Korea, Republic of, United States, Pakistan, Russian Federation, India, Czech Republic, Hungary, France
UCB Biopharma SRL

Terminated

A Study to Investigate the Long-term Safety, Tolerability, and Efficacy of Rozanolixizumab in Study Participants With Persistent or Chronic Primary Immune Thrombocytopenia (ITP) (myOpportunITy3)

Primary Immune Thrombocytopenia

United States, China, Georgia, Germany, Hungary, Italy, Japan, Moldova, Republic of, Poland, Russian Federation, Spain, Taiwan, Ukraine, United Kingdom
Kezar Life Sciences, Inc.

Withdrawn

A Phase 2 Study to Evaluate the Safety and Efficacy of KZR-616 in Patients With AIHA and ITP (MARINA)

Immune Thrombocytopenia | Autoimmune Hemolytic Anemia

Poland, United States, Australia, Italy, Russian Federation
GlaxoSmithKline

Completed

Study of a New Medication for Childhood Chronic Immune Thrombocytopenia (ITP), a Blood Disorder of Low Platelet Counts That Can Lead to Bruising Easily, Bleeding Gums, and/or Bleeding Inside the Body. (PETIT2)

Idiopathic Thrombocytopenic Purpura

Thailand, Israel, Poland, Russian Federation, Spain, Germany, United Kingdom, Taiwan, Hong Kong, Czech Republic, Italy, United States, Argentina
UCB Biopharma SRL

Terminated

A Study to Evaluate the Efficacy, Safety, and Tolerability of Rozanolixizumab in Adult Study Participants With Persistent or Chronic Primary Immune Thrombocytopenia (ITP) (myOpportunITy1)

Primary Immune Thrombocytopenia

United States, Bulgaria, France, Georgia, Greece, Hungary, Italy, Japan, Korea, Republic of, Moldova, Republic of, Poland, Romania, Russian Federation, Taiwan, Ukraine, United Kingdom
GlaxoSmithKline

Completed

LENS - Long-term Eltrombopag Observational Study (LENS)

Purpura, Thrombocytopaenic, Idiopathic

United States, Bulgaria, Italy, Peru, Russian Federation, Canada, France, Germany, Hong Kong, Spain, Sweden, United Kingdom, Hungary, Poland, Ukraine, Czech Republic, India, Australia, Tunisia, Puerto Rico, Pakistan
GlaxoSmithKline

Completed

RAISE: Randomized Placebo-Controlled Idiopathic Thrombocytopenic Purpura (ITP) Study With Eltrombopag (RAISE)

Purpura, Thrombocytopaenic, Idiopathic

United States, Taiwan, Italy, Poland, Peru, Canada, Denmark, Germany, Slovakia, Spain, United Kingdom, New Zealand, China, Greece, Hong Kong, Russian Federation, Austria, Netherlands, Czech Republic, France, India, Ukraine, Tunisia, F... and more
Sobi, Inc.

Active, not recruiting

Avatrombopag for the Treatment of Thrombocytopenia in Pediatric Subjects With Immune Thrombocytopenia for ≥6 Months

Immune Thrombocytopenia

United States, France, Germany, Hungary, Poland, Russian Federation, Turkey, Ukraine, United Kingdom
Novartis Pharmaceuticals

Completed

EXTEND (Eltrombopag Extended Dosing Study) (EXTEND)

Purpura, Thrombocytopaenic, Idiopathic

United Kingdom, Hong Kong, United States, Germany, Italy, Netherlands, Spain, Taiwan, Thailand, Canada, Denmark, Pakistan, Romania, Slovenia, Russian Federation, Slovakia, Sweden, Poland, China, New Zealand, Ukraine, Australia, Austria and more
argenx

Active, not recruiting

A Long-term Study to Assess the Safety and Efficacy of Efgartigimod in Adult Patients With Primary Immune Thrombocytopenia (ITP). (ADVANCE+)

Primary Immune Thrombocytopenia

United States, Austria, Belgium, Bulgaria, Czechia, France, Georgia, Germany, Hungary, Italy, Japan, Netherlands, Poland, Russian Federation, Spain, Turkey, United Kingdom, Ukraine
argenx

Recruiting

A Phase 3 Study to Evaluate the Safety and Efficacy of Efgartigimod PH20 Subcutaneous in Adult Patients With Primary Immune Thrombocytopenia (ADVANCE SC+)

Primary Immune Thrombocytopenia

United States, Australia, Bulgaria, China, Georgia, Greece, Italy, Japan, Poland, Portugal, Romania, Russian Federation, Thailand, Turkey, Argentina, Chile, Ireland, Jordan, Tunisia, Korea, Republic of, Mexico, New Zealand, South Africa and more
Amgen

Completed

Long-term Study of Romiplostim in Thrombocytopenic Pediatric Patients With Immune Thrombocytopenia (ITP)

Immune Thrombocytopenia

United States, Canada, Belgium, Czechia, Mexico, Turkey, Australia, Spain, France, Israel, Hungary, South Africa, Poland, Russian Federation, United Kingdom, Brazil, Switzerland
argenx

Completed

A Study to Assess the Efficacy and Safety of Efgartigimod in Adult Patients With Primary Immune Thrombocytopenia (ITP). (ADVANCE)

Primary Immune Thrombocytopenia

United States, Austria, Belgium, Bulgaria, Czechia, France, Georgia, Germany, Hungary, Italy, Japan, Netherlands, Poland, Russian Federation, Spain, Turkey, Ukraine, United Kingdom
argenx

Active, not recruiting

A Study to Evaluate the Efficacy and Safety of Efgartigimod PH20 Subcutaneous in Adult Patients With Primary Immune Thrombocytopenia (ADVANCE SC)

Primary Immune Thrombocytopenia

United States, France, Georgia, Germany, Italy, Japan, Poland, Russian Federation, Spain, Turkey, United Kingdom, Argentina, Australia, Bulgaria, Chile, China, Denmark, Greece, Ireland, Israel, Jordan, Korea, Republic of, Mexico, New... and more
Principia Biopharma, a Sanofi Company

Recruiting

Study to Evaluate Rilzabrutinib in Adults and Adolescents With Persistent or Chronic Immune Thrombocytopenia (ITP) (LUNA 3)

Immune Thrombocytopenia

United States, China, Argentina, Australia, Brazil, Canada, France, Hungary, Israel, Korea, Republic of, Mexico, Russian Federation, Singapore, Spain, Thailand, United Kingdom, Austria, Chile, Germany, Italy, Japan, Netherlands, Norway and more

Clinical Trials on Purpura in Russian Federation

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Angola

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations